Search - tctmd.com

Displaying 1 - 3 of 3

Sort: Relevancy | Date

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

News Conference News VIVA 2016

Bioresorbable Scaffold Shows Sustained Promise in Superficial Femoral and Iliac Artery Lesions

September 22, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

September 21, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.